ERIBULIN MESYLATE .5 mg/mL

Eribulin Mesylate .5 mg/mL is an injectable medication used in cancer treatment. This single-dose vial is designed for intravenous administration and is manufactured by Hikma Pharmaceuticals USA Inc.

Eribulin Mesylate is primarily used in the treatment of certain types of cancer. It is often prescribed for metastatic breast cancer and other advanced cancers. The medication works by targeting cancer cells to slow their growth and spread. Patients should consult their healthcare provider to determine if Eribulin Mesylate is suitable for their specific condition.

Common effects of Eribulin Mesylate may include fatigue, nausea, and hair loss. Some patients may experience peripheral neuropathy, which can cause numbness or tingling in the hands and feet. It is important to discuss any side effects with a healthcare professional to manage them effectively.

Eribulin Mesylate should be handled with care, as it is a potent medication. It is essential to follow proper storage and administration guidelines to ensure safety. Patients should inform their healthcare provider about any allergies or medical conditions before starting treatment. Pregnant women should avoid handling the medication due to potential risks.

Eribulin Mesylate may interact with other medications, including those that affect liver function. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should be avoided during treatment, as it may exacerbate side effects.